Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 480 clinical trials
Featured trial
AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

  • 112 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

  • 171 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

  • 112 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789) in the Very High Risk Stratum.

AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789) in the Very High Risk Stratum.

  • 216 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701

  • 365 views
  • 08 Nov, 2020
  • 1 location
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD

  • 0 views
  • 25 May, 2022
  • 20 locations
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

This is a single arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T( ssCART-19) combined with feeding T cells (FTCs) as consolidation therapy in patients diagnosed with de novo Philadelphia chromosome positive CD19+ B-ALL. The study will contain the following sequential phases: screening, lymphocyte …

  • 0 views
  • 24 May, 2022
  • 1 location
Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia

Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia

  • 0 views
  • 24 Sep, 2021
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

This study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with ALL Bcr / Abl positive. To determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients. To determine whether this association can increase the rate and quality …

  • 1 views
  • 22 Mar, 2022
  • 1 location
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

20-25% of patients over 15 years with acute lymphoblastic leukemia (ALL) have the Philadelphia chromosome or BCR-ABL rearrangement. Traditionally, intensive chemotherapy followed by

  • 103 views
  • 26 Mar, 2022
  • 73 locations